The results of a placebo-controlled randomised trial of remdesivir in COVID-19 patients have been published in the Lancet. Supported by the ISARIC Support Centre, scientists in China launched a trial of remdesivir in patients hospitalised with COVID-19. The results found no clinical benefit from use of the drug; however, while not statistically significant, the time to clinical improvement and duration of invasive mechanical ventilation were shorter in people treated with remdesivir.
